Lee JS, et al. - In patients with gout and fatty liver disease (FLD), researchers compared the hepatotoxicity of febuxostat and allopurinol and the clinical factors correlated with hepatotoxicity. Gout patients treated with allopurinol or febuxostat who were diagnosed with fatty liver based on ultrasonography or computed tomography were included. By Cox regression analysis, the factors associated with hepatotoxicity were evaluated. According to findings, febuxostat was well tolerated in gout and FLD patients among the 32 patients studied. The presence of diabetes and use of colchicine, however, may increase hepatotoxicity risk.